article thumbnail

Consensus statement on safety of combining transarterial radioembolization with 90yttrium microspheres with systemic anticancer agents for the treatment of liver malignancy

JVIR

To provide guidance, via multidisciplinary consensus statements, on the safety interactions between systemic anticancer agents (such as radiosensitizing chemotherapy, immunotherapy, targeted therapy and peptide receptor radionuclide therapy) and transarterial radioembolization (TARE) with yttrium-90 (90Y) labeled microspheres in the treatment of primary (..)

article thumbnail

CEUS adds to locoregional therapy for liver disease

AuntMinnie

This puts shear stress on the tumor endothelium and activates the production of ceramide, a radiosensitizer. Here, transient cavitation is activated via ultrasound-triggered microbubble destruction. The increase in ceramide leads to an increase in tumor cell death. The average tumor diameter recorded was 4.2

Disease 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Radiation doses estimated in infants with congenital heart disease

AuntMinnie

Ionizing radiation] exposure in early childhood may be associated with an increased risk of malignancy with neonates at especially higher risk due to their higher radiosensitivity and longer life expectancy than adults,” according to presenter Jeannette Wong-Siegel, MD, of the University of Washington in St. Louis, and colleagues.

article thumbnail

Abstract No. 360 Safety of Transarterial Radioembolization Plus Adjuvant Systemic Capecitabine for Treatment of Unresectable Biliary Tract Cancer

JVIR

It also acts as a radiosensitizer that can be combined with transarterial radioembolization (TARE) to treat primary and secondary liver tumors. Capecitabine has been proven effective as adjuvant chemotherapy for resectable biliary tract cancer (BTC).

article thumbnail

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

This may be due to inhibition of the MEK-MAPK pathway during DNA damage response, resulting in radiosensitization of cancer cells to 177Lu-rhPSMA-10.1. Results from this preclinical study presented at AACR demonstrated a synergistic therapeutic effect between 177Lu-rhPSMA-10.1 and an MEK inhibitor.

article thumbnail

TeleDaaS Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

Imaging Technology

“I anticipate that the benefit of radiopharmaceuticals will be maximized by combining radiopharmaceutical therapies with a vast array of other agents including immunotherapies, chemotherapeutics, radiosensitizers and radioprotectors.

Clinic 78
article thumbnail

5 Recommendations to Achieve Excellence in Pediatric Medical Imaging

Everything Rad

Not only are children more radiosensitive than adults (the cancer risk per unit dose of ionizing radiation is higher), but children also have a longer expected lifetime, which puts them at greater risk of cancer following radiation exposure.(1) The balance of dose and image quality is even more important in pediatric medical imaging.